464 related articles for article (PubMed ID: 14724435)
1. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation.
Yang Z; Chen M; Ellett JD; Fialkow LB; Carter JD; Nadler JL
Transplantation; 2004 Jan; 77(1):55-60. PubMed ID: 14724435
[TBL] [Abstract][Full Text] [Related]
2. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice.
Yang ZD; Chen M; Wu R; McDuffie M; Nadler JL
Diabetologia; 2002 Sep; 45(9):1307-14. PubMed ID: 12242464
[TBL] [Abstract][Full Text] [Related]
3. Inflammation blockade improves pancreatic islet function.
Yang Z; Chen M; Carter JD; Ellett JD; Smith KM; Nadler JL
Transplant Proc; 2004 Nov; 36(9):2864-5. PubMed ID: 15621169
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory blockade improves human pancreatic islet function and viability.
Yang Z; Chen M; Ellett JD; Carter JD; Brayman KL; Nadler JL
Am J Transplant; 2005 Mar; 5(3):475-83. PubMed ID: 15707401
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of thioredoxin in islets transduced by a lentiviral vector prolongs graft survival in autoimmune diabetic NOD mice.
Chou FC; Sytwu HK
J Biomed Sci; 2009 Aug; 16(1):71. PubMed ID: 19671194
[TBL] [Abstract][Full Text] [Related]
6. Triptolide ameliorates autoimmune diabetes and prolongs islet graft survival in nonobese diabetic mice.
Huang SH; Lin GJ; Chu CH; Yu JC; Chen TW; Chen YW; Chien MW; Chu CC; Sytwu HK
Pancreas; 2013 Apr; 42(3):442-51. PubMed ID: 23146919
[TBL] [Abstract][Full Text] [Related]
7. Lisofylline, a novel antiinflammatory agent, protects pancreatic beta-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism.
Chen M; Yang Z; Wu R; Nadler JL
Endocrinology; 2002 Jun; 143(6):2341-8. PubMed ID: 12021199
[TBL] [Abstract][Full Text] [Related]
8. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice.
Yang Z; Chen M; Fialkow LB; Ellett JD; Wu R; Nadler JL
Pancreas; 2003 May; 26(4):e99-104. PubMed ID: 12717280
[TBL] [Abstract][Full Text] [Related]
9. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
Fu F; Hu S; Deleo J; Li S; Hopf C; Hoover J; Wang S; Brinkmann V; Lake P; Shi VC
Transplantation; 2002 May; 73(9):1425-30. PubMed ID: 12023620
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice.
Smith DK; Korbutt GS; Suarez-Pinzon WL; Kao D; Rajotte RV; Elliott JF
Transplantation; 1997 Oct; 64(7):1040-9. PubMed ID: 9381527
[TBL] [Abstract][Full Text] [Related]
11. Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents.
Gysemans C; Stoffels K; Giulietti A; Overbergh L; Waer M; Lannoo M; Feige U; Mathieu C
Diabetologia; 2003 Aug; 46(8):1115-23. PubMed ID: 12879250
[TBL] [Abstract][Full Text] [Related]
12. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice.
Lakey JR; Singh B; Warnock GL; Rajotte RV
Transplantation; 1994 Apr; 57(8):1213-7. PubMed ID: 8178349
[TBL] [Abstract][Full Text] [Related]
13. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine.
Casteels K; Waer M; Laureys J; Valckx D; Depovere J; Bouillon R; Mathieu C
Transplantation; 1998 May; 65(9):1225-32. PubMed ID: 9603172
[TBL] [Abstract][Full Text] [Related]
14. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice.
Drage M; Zaccone P; Phillips JM; Nicoletti F; Dawson J; Andrew Bradley J; Cooke A
Transplantation; 2002 Sep; 74(5):611-9. PubMed ID: 12352875
[TBL] [Abstract][Full Text] [Related]
15. Differences in suppressor of cytokine signaling-1 (SOCS-1) expressing islet allograft destruction in normal BALB/c and spontaneously-diabetic NOD recipient mice.
Solomon M; Flodström-Tullberg M; Sarvetnick N
Transplantation; 2005 May; 79(9):1104-9. PubMed ID: 15880051
[TBL] [Abstract][Full Text] [Related]
16. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody.
Molano RD; Pileggi A; Berney T; Poggioli R; Zahr E; Oliver R; Malek TR; Ricordi C; Inverardi L
Transplantation; 2003 Jun; 75(11):1812-9. PubMed ID: 12811239
[TBL] [Abstract][Full Text] [Related]
17. Lisofylline: a potential lead for the treatment of diabetes.
Yang Z; Chen M; Nadler JL
Biochem Pharmacol; 2005 Jan; 69(1):1-5. PubMed ID: 15588708
[TBL] [Abstract][Full Text] [Related]
18. Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts.
Gysemans CA; Waer M; Valckx D; Laureys JM; Mihkalsky D; Bouillon R; Mathieu C
Diabetes; 2000 Dec; 49(12):1992-7. PubMed ID: 11117999
[TBL] [Abstract][Full Text] [Related]
19. Triptolide prolonged allogeneic islet graft survival in chemically induced and spontaneously diabetic mice without impairment of islet function.
Xin MJ; Cui SH; Liu S; Sun HC; Li F; Sun JB; Luo B
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):312-8. PubMed ID: 20525560
[TBL] [Abstract][Full Text] [Related]
20. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10.
Faust A; Rothe H; Schade U; Lampeter E; Kolb H
Transplantation; 1996 Sep; 62(5):648-52. PubMed ID: 8830831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
